MX2023000056A - Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). - Google Patents

Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).

Info

Publication number
MX2023000056A
MX2023000056A MX2023000056A MX2023000056A MX2023000056A MX 2023000056 A MX2023000056 A MX 2023000056A MX 2023000056 A MX2023000056 A MX 2023000056A MX 2023000056 A MX2023000056 A MX 2023000056A MX 2023000056 A MX2023000056 A MX 2023000056A
Authority
MX
Mexico
Prior art keywords
jak2
urea compounds
inhibitors
tricyclic urea
tricyclic
Prior art date
Application number
MX2023000056A
Other languages
English (en)
Inventor
David M Burns
Eddy W Yue
Brent Douty
Hao Feng
Jun Pan
Leah C Konkol
Xun Liu
Liangxing Wu
Yu Bai
Joseph Barbosa
Wenqing Yao
Song Mei
Yanran Ai
Haisheng Wang
Daniel Levy
Onur Atasoylu
Cheng-Tsung Lai
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2023000056A publication Critical patent/MX2023000056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud proporciona compuestos de urea tricíclicos que modulan la actividad de la variante V7F de JAK2, que son útiles en el tratamiento de varias enfermedades, incluyendo cáncer.
MX2023000056A 2020-07-02 2021-07-01 Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). MX2023000056A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047483P 2020-07-02 2020-07-02
US202163164302P 2021-03-22 2021-03-22
PCT/US2021/040185 WO2022006457A1 (en) 2020-07-02 2021-07-01 Tricyclic urea compounds as jak2 v617f inhibitors

Publications (1)

Publication Number Publication Date
MX2023000056A true MX2023000056A (es) 2023-04-12

Family

ID=77104160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000056A MX2023000056A (es) 2020-07-02 2021-07-01 Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).

Country Status (17)

Country Link
US (2) US11780840B2 (es)
EP (1) EP4175719A1 (es)
JP (1) JP2023533724A (es)
KR (1) KR20230057341A (es)
CN (1) CN116323612A (es)
AU (1) AU2021300429A1 (es)
BR (1) BR112023000047A2 (es)
CA (1) CA3188639A1 (es)
CL (1) CL2022003834A1 (es)
CO (1) CO2023001165A2 (es)
CR (1) CR20230057A (es)
EC (1) ECSP23007180A (es)
IL (1) IL299612A (es)
MX (1) MX2023000056A (es)
PE (1) PE20231739A1 (es)
TW (1) TW202216713A (es)
WO (1) WO2022006457A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
US20230295124A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN115403581B (zh) * 2022-07-18 2023-03-28 英矽智能科技(上海)有限公司 作为irak4抑制剂的杂环化合物
WO2024041586A1 (zh) * 2022-08-25 2024-02-29 启元生物(杭州)有限公司 一种jak激酶抑制剂的前药
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
JPS62209062A (ja) 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DE4344452A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
SK48199A3 (en) 1996-10-16 2000-01-18 Icn Pharmaceuticals Purine l-nucleosides, analogs and uses thereof
US6177464B1 (en) 1997-03-14 2001-01-23 Sepracor, Inc. Ring opening metathesis of alkenes
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
CN1138778C (zh) 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
JP2000123973A (ja) 1998-10-09 2000-04-28 Canon Inc 有機発光素子
DE19900545A1 (de) 1999-01-11 2000-07-13 Basf Ag Verwendung von Pyrimidinderivaten zur Prophylaxe und Therapie der zerebralen Ischämie
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2001023389A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
WO2001047891A1 (fr) 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
EP1267876A1 (en) 2000-03-23 2003-01-02 Merck & Co., Inc. Thrombin inhibitors
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
WO2002091830A1 (en) 2001-05-15 2002-11-21 E.I. Du Pont De Nemours And Company Pyridinyl fused bicyclic amide as fungicides
US20030139431A1 (en) 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
JP2003107641A (ja) 2001-09-27 2003-04-09 Fuji Photo Film Co Ltd ハロゲン化銀感光材料
EP1471910A2 (en) 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
AU2003211594A1 (en) 2002-03-05 2003-09-16 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
WO2004024693A1 (ja) 2002-08-13 2004-03-25 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
BR0315053A (pt) 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
CA2500952C (en) 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
JP4552651B2 (ja) 2002-10-30 2010-09-29 味の素株式会社 複素環化合物
US7432275B2 (en) 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
WO2004091485A2 (en) 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
WO2005028478A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
CA2546493A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
CA2565200C (en) 2004-05-07 2013-12-24 Exelixis, Inc. Raf modulators and methods of use
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
US7569580B2 (en) 2004-06-03 2009-08-04 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as HCV inhibitors
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006045096A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
ATE472543T1 (de) 2005-01-07 2010-07-15 Pfizer Prod Inc Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
KR100926399B1 (ko) 2005-04-06 2009-11-12 아이알엠 엘엘씨 디아릴아민―함유 화합물 및 조성물, 및 스테로이드 호르몬핵 수용체의 조절제로서의 그들의 용도
CN101233132A (zh) 2005-05-09 2008-07-30 海德拉生物科学公司 调节trpv3功能的化合物
US20070049559A1 (en) 2005-06-28 2007-03-01 Bruce Pfeffer Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
ES2601178T3 (es) 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
MX2008004024A (es) 2005-09-23 2009-02-27 Schering Corp Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos.
WO2007047653A2 (en) 2005-10-17 2007-04-26 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
EP2024342A2 (en) 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
WO2007133637A2 (en) 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007136465A2 (en) 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.
AR061664A1 (es) 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
EP2041138B1 (en) 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
GB0614052D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008022152A2 (en) 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19
US7678803B2 (en) 2006-08-24 2010-03-16 Serenex, Inc. Quinazoline derivatives for the treatment of cancer
RU2009119181A (ru) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
KR100789731B1 (ko) 2006-11-15 2008-01-03 전남대학교산학협력단 파이로시퀀싱을 이용한 ｊａｋ2 ｖ617ｆ 돌연변이의 정량적검출방법, 시발체 및 키트
US7723355B2 (en) 2006-11-20 2010-05-25 Bristol-Myers Squibb Company 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CA2675288A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
ATE525375T1 (de) 2007-03-13 2011-10-15 Merck Sharp & Dohme Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
EP1972627A1 (en) 2007-03-19 2008-09-24 Technische Universität Carolo-Wilhelmina zu Braunschweig Amino-napthyridine derivatives
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2008135524A2 (en) 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted anthranilamides and analogues, manufacturing and use thereof as medicaments
EP2481735A1 (en) 2007-05-09 2012-08-01 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
SG185255A1 (en) 2007-09-26 2012-11-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010006130A2 (en) 2008-07-09 2010-01-14 Envivo Pharmaceuticals, Inc. Pde-10 inhibitors
JP5281647B2 (ja) 2008-09-08 2013-09-04 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤
WO2010039518A2 (en) 2008-09-23 2010-04-08 Rigel Pharmaceuticals, Inc. Tricyclic carbamate jak inhibitors
CN102245610B (zh) 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
CA2747158A1 (en) 2008-12-16 2010-07-08 Sirtris Pharmaceuticals, Inc. Phthalazinone and related analogs as sirtuin modulators
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
BRPI0923796A2 (pt) 2008-12-29 2018-05-29 Southern Research Institute compostos antivirais, tratamento e ensaio
JP2012519211A (ja) 2009-03-02 2012-08-23 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節化合物としての８−置換キノリンおよび関連類似体
AR076126A1 (es) 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2010111303A2 (en) 2009-03-23 2010-09-30 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
JP5813626B2 (ja) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション 新規抗炎症剤
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2010141062A1 (en) 2009-06-04 2010-12-09 Ludwig Institute For Cancer Research Ltd. Inhibitors of constitutively active janus kinases and uses thereof
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2010143169A2 (en) 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
KR101669311B1 (ko) * 2009-09-03 2016-10-25 브리스톨-마이어스 스큅 컴퍼니 Ｊａｋ２ 억제제, 및 골수증식성 질환 및 암의 치료를 위한 그의 용도
KR101097315B1 (ko) 2009-10-12 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
BR112012010085B1 (pt) 2009-10-29 2020-02-04 Genosco composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
SG181147A1 (en) 2009-12-01 2012-07-30 Abbott Lab Novel tricyclic compounds
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
CA2785284A1 (en) 2009-12-25 2011-06-30 Tomoyuki Kamino Novel aryl urea derivative
KR20140015162A (ko) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
PE20130211A1 (es) 2010-04-02 2013-03-22 Senomyx Inc Modificador del sabor dulce
US20130109687A1 (en) 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
EP3034509B1 (en) 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
US20140031355A1 (en) 2010-11-04 2014-01-30 Amgen Inc. Heterocyclic compounds and their uses
CA2818389A1 (en) 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US20120214824A1 (en) 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
CN102603628B (zh) 2010-12-22 2016-08-17 香港理工大学 作为抗癌试剂的喹啉衍生物
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012097479A1 (en) 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2688890B1 (en) 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9433219B2 (en) 2011-04-20 2016-09-06 The Regents Of The University Of California Fungi antagonistic to xylella fastidiosa
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
WO2013033093A1 (en) 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013033981A1 (zh) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 一类2,7-萘啶衍生物及其制备方法和应用
EP2748169A4 (en) 2011-09-30 2015-06-17 Kineta Inc ANTI-VIRAL COMPOUNDS
WO2013062987A1 (en) 2011-10-24 2013-05-02 New York University Methods for identifying janus kinase (jak) modulators for therapeutics
WO2013067036A1 (en) 2011-10-31 2013-05-10 Rutgers, The State University Of New Jersey Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
KR102116000B1 (ko) 2012-05-08 2020-05-29 메르크 앤드 씨에 18f-표지된 폴레이트/안티폴레이트 유사체들
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
CN104395298A (zh) 2012-06-22 2015-03-04 住友化学株式会社 稠合杂环化合物
TWI631097B (zh) 2012-07-27 2018-08-01 百健Ｍａ公司 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物
JP6363075B2 (ja) 2012-08-07 2018-07-25 メルク パテント ゲーエムベーハー 金属錯体
WO2014051653A1 (en) 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
FR2996129B1 (fr) 2012-09-28 2014-12-19 Oreal Procede de coloration capillaire mettant en oeuvre au moins un derive d'heterocycle azote, un sel de manganese ou de zinc, du peroxyde d'hydrogene et du (bi)carbonate
BR112015010396A2 (pt) 2012-11-07 2017-07-11 Novartis Ag terapia de combinação
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
AU2014212465B2 (en) 2013-01-29 2018-07-12 Biogen Ma Inc. S1P modulating agents
KR102081281B1 (ko) 2013-02-08 2020-05-28 삼성디스플레이 주식회사 유기 발광 소자
KR102147424B1 (ko) 2013-03-08 2020-08-25 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
US9333213B2 (en) 2013-03-15 2016-05-10 Duke University Prochelators as broad-spectrum antimicrobial agents and methods of use
WO2014203152A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
KR101682020B1 (ko) 2013-06-28 2016-12-02 제일모직 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
AU2014285733B2 (en) 2013-07-05 2019-05-16 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
CN105377253A (zh) 2013-07-16 2016-03-02 奇尼塔公司 抗病毒化合物、医药组合物和其使用方法
US20160346291A1 (en) 2013-08-21 2016-12-01 Resverlogix Corp Compositions and therapeutic methods for accelerated plaque regression
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
US10407394B2 (en) 2013-10-04 2019-09-10 Merck Patent Gmbh Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices
CN105814022B (zh) 2013-12-09 2018-09-28 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合的二环杂芳族衍生物
CN104725249B (zh) 2013-12-20 2019-02-12 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
CN104860931A (zh) 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
RU2695815C9 (ru) 2014-03-24 2019-10-28 Гуандун Чжуншэн Фармасьютикал Ко., Лтд Хинолиновые производные в качестве ингибиторов smo
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CN105461714B (zh) 2014-09-29 2017-11-28 山东轩竹医药科技有限公司 并环类pi3k抑制剂
KR102308118B1 (ko) 2014-10-22 2021-10-01 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104311426A (zh) 2014-10-27 2015-01-28 厦门大学 芳香硝基乙烯化合物的新用途
CN105732591B (zh) 2014-12-31 2019-10-25 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
WO2016116900A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10487075B2 (en) 2015-02-11 2019-11-26 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3277293A4 (en) 2015-03-30 2019-01-16 Jeffrey Thomas Loh PROCESS FOR IN VITRO PRODUCTION OF BLOOD PLATES AND COMPOSITIONS AND USES THEREOF
CN105481765A (zh) 2015-04-15 2016-04-13 江苏艾凡生物医药有限公司 一类用于治疗心力衰竭的酰腙类衍生物
KR101904300B1 (ko) 2015-04-15 2018-10-04 삼성에스디아이 주식회사 유기 광전자 소자용 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
WO2016190847A1 (en) 2015-05-26 2016-12-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
RU2719477C2 (ru) 2015-06-22 2020-04-17 Оно Фармасьютикал Ко., Лтд. Соединение, ингибирующее brk
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102192691B1 (ko) 2015-06-30 2020-12-17 (주)피엔에이치테크 유기발광 화합물 및 이를 포함하는 유기전계발광소자
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017029601A1 (en) 2015-08-17 2017-02-23 Lupin Limited Heteroaryl derivatives as parp inhibitors
CN108289957A (zh) 2015-10-02 2018-07-17 达纳-法伯癌症研究所股份有限公司 溴区结构域抑制剂和检查点阻断的组合疗法
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CA3002888A1 (en) 2015-10-26 2017-05-04 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017090002A2 (en) 2015-11-27 2017-06-01 Gvk Biosciences Private Limited Inhibitors of pi3 kinases
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
ES2844374T3 (es) 2015-12-22 2021-07-22 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
AU2017281903B2 (en) 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
JP6903731B2 (ja) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
GB201615282D0 (en) 2016-09-08 2016-10-26 Univ Bath Tankyrase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
JP7076441B2 (ja) 2016-11-02 2022-05-27 ヤンセン ファーマシューティカ エヌ．ベー． ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン誘導体
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PT3559009T (pt) 2016-12-22 2021-05-04 Calithera Biosciences Inc Composições e métodos para inibir a atividade da arginase
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US20200000099A1 (en) 2017-01-31 2020-01-02 The Regents Of The University Of California Organisms antagonistic to xylella fastidiosa
EP3619210A4 (en) 2017-05-01 2020-12-02 Sanford Burnham Prebys Medical Discovery Institute LOW MOLECULAR PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND USES THEREOF
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3638235A4 (en) 2017-06-14 2021-06-09 Trevena, Inc. COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING IT
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. HETEROARYL COMPOUNDS AS INHIBITORS OF THE NECROSIS, COMPOSITION AND METHOD OF USE THEREOF
KR20200058443A (ko) 2017-09-25 2020-05-27 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
AU2018345523B2 (en) 2017-10-02 2021-10-21 Merck Sharp & Dohme Llc Chromane monobactam compounds for the treatment of bacterial infections
CN109575022B (zh) 2017-12-25 2021-09-21 成都海博锐药业有限公司 一种化合物及其用途
CN109608504B (zh) 2017-12-28 2022-04-05 广州华睿光电材料有限公司 有机金属配合物、聚合物、混合物、组合物和有机电子器件
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
US20200375987A1 (en) 2018-01-03 2020-12-03 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors and methods of use thereof
JP7169005B2 (ja) 2018-01-16 2022-11-10 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジフェニルアミノピリミジン系化合物
US20190256492A1 (en) 2018-02-19 2019-08-22 Washington University Alpha-synuclein ligands
WO2019177975A1 (en) 2018-03-12 2019-09-19 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN111836814B (zh) 2018-05-11 2023-10-20 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
CN111484480B (zh) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
JP7371221B2 (ja) 2019-07-26 2023-10-30 珠海宇繁生物科技有限責任公司 Ｉｒａｋ４キナーゼ阻害剤及びその調製方法
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺

Also Published As

Publication number Publication date
AU2021300429A1 (en) 2023-02-16
TW202216713A (zh) 2022-05-01
US20240150354A1 (en) 2024-05-09
CN116323612A (zh) 2023-06-23
CA3188639A1 (en) 2022-01-06
EP4175719A1 (en) 2023-05-10
WO2022006457A1 (en) 2022-01-06
IL299612A (en) 2023-03-01
BR112023000047A2 (pt) 2023-03-14
CR20230057A (es) 2023-08-15
US11780840B2 (en) 2023-10-10
ECSP23007180A (es) 2023-05-31
JP2023533724A (ja) 2023-08-04
PE20231739A1 (es) 2023-10-31
CO2023001165A2 (es) 2023-04-27
US20220169649A1 (en) 2022-06-02
CL2022003834A1 (es) 2023-06-23
KR20230057341A (ko) 2023-04-28

Similar Documents

Publication Publication Date Title
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
JOP20210154B1 (ar) مثبطات kif18a
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021007104A (es) Inhibidores de kif18a.
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2022001181A (es) Inhibidores de kif18a.
MX2020008767A (es) Disruptores del dímero egfr y uso de estos.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
TN2018000383A1 (en) Pde9 inhibitors for treatment of peripheral diseases.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2022001004A (es) Inhibidores de enzimas.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
NZ740817A (en) Pcna inhibitors
MX2022000811A (es) Inhibidores de enzimas.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.